PropertyValue
is ?:annotates of
?:authorAffiliation
  • [\'Janssen Vaccines & Prevention B.V., Leiden, The Netherlands.\', \'Janssen R&D, Beerse, Belgium.\', \'Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA.\', \'Lucidity Biomedical Consulting, Granada, Spain.\', \'Ragon Institute of MGH, MIT and Harvard, Cambridge, MA, USA.\', \'Harvard Medical School, Boston, MA, USA.\', \'Massachusetts Consortium on Pathogen Readiness, Boston, MA, USA.\', \'Janssen Vaccines & Prevention B.V., Leiden, The Netherlands. RZahn@its.jnj.com.\']
?:citedBy
  • -1
?:creator
?:doi
?:doi
  • 10.1038/s41467-021-26117-x
?:hasPublicationType
?:journal
  • Nature communications
is ?:pmid of
?:pmid
?:pmid
  • 34620860
?:publication_isRelatedTo_Disease
?:rankingScore_SJR
  • 6.582
?:rankingScore_hIndex
  • 198
is ?:relation_isRelatedTo_publication of
?:title
  • SARS-CoV-2 binding and neutralizing antibody levels after Ad26.COV2.S vaccination predict durable protection in rhesus macaques.
?:type
?:year
  • 2021

Metadata

Anon_0  
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://purl.org/net/provenance/ns#DataItem>
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://www.w3.org/2004/03/trix/rdfg-1/Graph>
<http://xmlns.com/foaf/0.1/primaryTopic> <https://research.tib.eu/covid-19/entity/34620860>
<http://xmlns.com/foaf/0.1/topic> Anon_0
<http://www.ontologydesignpatterns.org/cp/owl/informationrealization.owl#realizes> <https://research.tib.eu/covid-19/data/entity/34620860>
<http://purl.org/net/provenance/ns#createdBy>
Anon_1   (more)
expand all